Transcript Lead - AOEC
Lead Sources of Occupational Exposure, Clinical Toxicology, and Control Lead in the Environment • Lead (207Pb) is a natural element, heavy metal, end product of radionuclide decay • Radioactive lead (210Pb, t1/2 = 22 y) is a convenient way to trace lead • Lead was insignificant environmentally until about 1800 • Human activity has mobilized lead in the environment Useful Properties of Lead • Ductility • Low melting point • Density, absorption of radiation, sound and vibration • Chemical properties (e.g. combines with nitrogen) • Resists acid and corrosion Historical Sources of Lead Exposure Ancient/Premodern History • Lead oxide as a sweetening agent • Lead pipes (“plumbing”) • Ceramics • Smelting and foundries Modern History • Gasoline • Ceramics • Crystal glass • Soldering – pipes – “tin” cans – car radiators • House paint Contemporary Sources of Lead Exposure • • • • • • • • Residue of leaded gasoline Lead smelting and recycling Solder (Pb + Sn), welding (minor) Metalworking Ammunition and explosives Exterior paints and remediation Avocational exposure in crafts Kohl and certain herbal remedies Future Sources of Exposure to Lead • Gasoline, in some developing countries • Plastics containing Pb additives (e.g. one type of “thin” Venetian blinds) • Compounding “litharge”, used in making ferrite ceramic magnets • Pb compounds with piezoelectric and thermoelectric properties • Unregulated cosmetics, remedies Settings for Lead Exposure • Smelting and metalworking • Lead sulfate battery operations • Activities related to firearms and ammunition • Crafts involving glass, ceramics • Hazardous waste disposal • Imported or customized products Biologically Important Properties of Lead • • • • • Readily combines with sulfide, sulfhydryls Affinity for bone and other calcified tissue Readily absorbed and mobilized in the body Cumulative body burden Narrow margin between population reference levels and toxicity levels • OrganoPb compounds more bioavailable Lead Exposure in Children • Pica and passive exposure: oral • Pb removed from gasoline • Blood Pb, FEP • CNS more likely to be affected • Needleman controversy Lead Exposure in Adults • Mostly occupational: inhalation • Maintenance at workplace • Peripheral neuropathy more common • Blood Pb, ZPP • Renal effects more likely Cardinal Symptoms of Lead Intoxication Acute • GI effects – colic, severe pain – severe constipation • Acute encephalopathy • Acute nephropathy Children • Growth retardation • Behavioural Chronic • Peripheral, central neuropathy • Cardiac toxicity • Chronic nephropathy • Saturnine gout • Reproductive effects • Hypertension? • Anemia Signs of Extreme Lead Toxicity • Acute lead encephalopathy – fatal in 25% – poor prognosis for full neurological recovery – severe clinical impairment in 40% • Severe lead colic • “Burtonian” lines (gingival deposition of Pb sulfide) Mechanisms of Damage to the Nervous System by Lead Central • Cerebral edema • Necrosis of brain tissue • Glial proliferation around blood vessels Peripheral • Demyelination • Reversible NCV • Irreversible axonal degeneration Neurological Manifestations of Lead Toxicity Central/Pediatric • Lethargy, wakeful • Irritability • Clumsiness, ataxia • Projectile vomiting • Visual s • Delerium, convulsions, coma • IQ performance Peripheral/Adult • Lead palsy – median n.c. slowing – wrist/foot drop – demyleinating disease • Lead colic • Muscle weakness • Behavioural, memory Anemia and Lead Toxicity • Normochromichypochromic, normocyticmicrocytic • Reduced rbc survival time • Compensatory rbc production – reticulocytosis • Basophilic stippling – variable – represents damaged cell organelles, RNA Haeme Synthesis and Lead Toxicity • Pb inhibits -aminolevulinic acid dehydratase -ALA in urine • Pb inhibits co-proporphyrinogen decarboxylase Co-proporphyrinogen in urine • Pb inhibits ferrochelatase Protoporphyrine IX accumulates in rbcs • FEP, ZPP tests are based on this Diagnostic Criteria for Lead Toxicity (CDC) • Blood – Blood lead > 80 g/dL – FEP > 190 g/dL – ZPP • Urinary Pb Excretion (24 hour) – Pb > 0.15 mg/L – -ALA > 19 mg/L – Coproporphyrin III > 150 g/L Other Considerations in the Diagnosis of Lead Toxicity • Blood lead is most generally useful • FEP not useful below about 20 g/dL • Evidence clearly suggests that children should be considered at risk if BPb > 10 g/dL • Early evidence that there may be risk at 5 g/dL • Congenital anomalies have been reported Toxicokinetics of Lead, I • Ingestion (children), inhalation (adults) • Readily absorbed by inhalation route • Slow absorption by ingestion, with Fe deficiency • OrganoPb compounds (e.g. Et4Pb) much more rapidly absorbed • Cumulative exposure Toxicokinetics of Lead, II • Carried by red cell, mostly bound to haemaglobin A2 • Rapidly distributed perfusion • Affinity for bone, which acts as sink (94%) • Bone constitutes reservoir in equilibrium with blood; turnover slow • t = 28 - 36 days in adult Toxicokinetics of Lead, III • Inorganic Pb is not metabolised • Organic (alkyl) Pb compounds are dealkylated in the liver • Dealkylation involves cytochrome P450 • Some alkyl Pb is dealkylated, stays behind as inorganic Pb, and remobilizes • Children have much less capacity to metabolize than adults Toxicokinetics of Lead, IV • Excretion of Pb generally reflects body burden, not route of exposure • Ingested Pb not absorbed passes in feces • Enterohepatic circulation, biliary secretion • Excretion by two pathways: – biliary excretion (major with high exposures) – urinary excretion (major) Susceptibility Factors Genetic Predispositions • Inborn errors of haeme metabolism (porphyrias) • Hereditary anemias (e.g. the thalassemias) Acquired Characteristics • Children < 6 y • Pregnant, lactating women • Nutritional deficiency, esp. Fe, Ca++, vit D • Neurological or renal disease • ?Alcohol abuse Occupational Exposure Levels OSHA PEL 0.05 mg/m3, 8-h TWA NIOSH REL 0.10 mg/m3, 10-h TWA; BEI, Pb compounds covered differ ACGIH TLV 0.05 mg/m3, 8-h TWA OSHA Pb Standard Actions BPb >60 on a single sample BPb > 50 ave last 3 samples BPb 40 - 60 BPb < 40 Medical removal Medical removal Action level is 50 RTW: Confirm 2 wks Repeat BPb q month Repeat BPb q month Repeat BPb q 2 months Repeat BPb q 6 months Management of Lead Exposure Adults • • • • • • • Prohibit eating, drinking, smoking at work Housekeeping Ventilation Personal protection Medical removal Control exposure to OSHA Pb standard Review other possible sources of contamination Management of Lead Exposure Children • Optimize nutrition, avoid fasting • Report through public health dept. • Home Pb abatement – – – – Dust control water food containers home and yard • Rule out passive exposure Chelation • Not a decision to be taken lightly • Requires close monitoring • Inefficient process, typically reducing body burden only 1 - 2 % • Chelating agents may not significantly reduce tissue levels, esp. in CNS Chelation with Agents Other than Succimer • Chelation can be dangerous! – May result in Ca++ depletion, hypercalcemia – May result in nephrotoxicity if serum Pb • Agents – CaNa2EDTA 1000-1500 mg/m2/d, iv – BAL 300 - 450 mg/m2/d, 50 - 75 mg/m2 q4h 3 - 5 d, im – D - penicillamine (second-line drug) Chelation with Succimer • Dimercaptosuccinic acid • Oral administration • Minimal side effects in decade of experience • Displaced D-penicillamine as oral agent since 1991 • If adverse reactions to succimer, EDTA, Dpenicillamine is the alternative Paediatric Chelation Therapy Encephalopathy - 1 • • • • • • A medical emergency! BAL and CaNa2•EDTA at 1500 mg/m2/d, iv Stat BAL + continuous EDTA infusion EDTA alone may cause deterioration Generally continued 5 days D/C BAL at 3 days, continuing EDTA if prompt response and BPb <50 g/dl Paediatric Chelation Therapy Encephalopathy - 2 • Fluid management critical – risk of cerebral edema, SIADH – monitor I/O, spec grav, electrolytes • NPO for first several days • Adequate fluid replacements – 1 ml/kcal/d energy requirements (100/kg first 10 kg, then 50 for next 10, thereafter 20) – Urine output: 0.5 ml/kcal/d or 350 - 500 ml/m2/d Paediatric Chelation Therapy Encephalopathy - 3 • Seizure control by benzodiazepines • Suspect cerebral edema – – – – – avoid LP mannitol, glycerol hyperosmotic therapy modest hyperventilation steroids more aggressive management not evaluated Paediatric Chelation Therapy BPb > 70 g/dl • If milder symptoms and/or blood Pb > 70 g/dl, chelation on regimen similar to encephalopathy • 3 days of BAL + 5 days EDTA • PICU for first few days • Repeated courses only if required: – Second course should follow >2 d – Third course by 10 - 14 d, to equilibrate Paediatric Chelation Therapy BPb 45 - 69 g/dl • If asymptomatic, treatment with succimer is preferred • Succimer initiated with 30 mg/kg/d or 1050 mg/m2/d in three divided doses 5 d • Succimer maintained at 20 mg/kg/d or 70 mg/m2/d in two divided doses 14 d • Consider hospitalization if home abatement is not possible Paediatric Chelation Therapy BPb 20 - 44 g/dl • CDC and AAP recommend environmental interventions but not chelation • These guidelines considered conservative • Reasonable to consider chelation if: – – – – Pb levels do not decline symptoms, even if subtle elevated FEP after Fe supplementation Age < 2 y Paediatric Chelation Therapy BPb 10 - 19 g/dl • Excessive exposure to Pb • Currently not considered as indication for chelation • Home Pb abatement and control of exposure is recommended Indications for Paediatric Therapy May Change • Safety of succimer may change recommendations • NIEHS is sponsoring a clinical trial: Treatment of Lead-Exposed Children (TLC) – – – – multicentre randomized, double-blind succimer v. placebo outcomes include developmental indices Adult Chelation Therapy - 1 • • • • • Indicated for symptomatic Pb toxicity Generally less effective Never a substitute for control of exposure Unethical to give chelation for prophylaxis Indications for chelation depend on symptoms and BPb (g/dl), not BPb alone Adult Chelation Therapy - 2 Encephalo pathy Symptoma tic Mild symptoms Asymptomatic Any BPb BAL + EDTA BPb > 100 BAL + EDTA BPb 70 - Succimer 100 po BPb < 70 Medical removal High dosages Lower dosages Adult Chelation Therapy - 3 • Encephalopathy: – BAL 450 mg/m2/d, 75 mg im q4h 5 d – EDTA 1500 mg/m2/d, iv 5 d – Start EDTA 4 hours after stat BAL • Symptomatic, BPb > 70 – BAL 300 - 450 mg/m2/d, 50 - 75 mg im q4h 3 -5d – EDTA 1000 - 1500, otherwise as above Adult Chelation Therapy - 4 • Mild Symptoms treated with Succimer – Succimer 700 - 1050 mg/m2/d – Give 350 mg/m2 (or 10 mg/kg) 5 d, then bid 14 d • The availability of a safe chelating agent does not mean that prophylaxis is acceptable. Every Case of Lead Toxicity is a Failure of Society • Lead toxicity is entirely preventable • This problem should not exist in 2000 • A worker exposed to lead represents an insult in the present • A child exposed to lead represents an assault on the future